AU Patent

AU2003228099A1 — Use of hmgb1 in the treatment of tissue damage and/or to promote tissue repair

Assigned to Centro Cardiologico Monzino Spa-Irccs · Expires 2004-01-23 · 22y expired

What this patent protects

It is described a composition comprising an effective amount of the HMGBl protein or functional parts thereof, of HMGBl expressing vectors, for the treatment of tissue damage and/or to promote tissue repair and regeneration. It is further described a composition comprising an eff…

USPTO Abstract

It is described a composition comprising an effective amount of the HMGBl protein or functional parts thereof, of HMGBl expressing vectors, for the treatment of tissue damage and/or to promote tissue repair and regeneration. It is further described a composition comprising an effective amount of an antagonist of the HMGBl protein for the treatment of adverse effects induced by necrotic tissue, such as recruitment and activation of mveloid cells, loss of the barrier function of endothelia, edema.

Drugs covered by this patent

Patent Metadata

Patent number
AU2003228099A1
Jurisdiction
AU
Classification
—
Expires
2004-01-23
Drug substance claim
No
Drug product claim
No
Assignee
Centro Cardiologico Monzino Spa-Irccs
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.